Effects of transglucosidase on diabetes, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial

Effects of transglucosidase on diabetes, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial - TG Effect on Diabete

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010318

Enrollment

Registered

2013-03-26

Start date

2007-09-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients

Interventions

Placebo 3 times/day after every meal Transglucosidase 100mg 3 times after every meal Transglucosidase 300mg 3 times after every meal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who were diagnosed to type-2 diabetes according to the diagnosis criteria of diabetes mellitus of the Japanese Diabetes Society. 2) Patients whose HbA1c level was between 5.8 and 7.5% at screening. 3) Patiens who had stable dosages of medication for at least 1 month. 4) Patients who were stable diabetes condition for at least 3 months (change in HbA1c less than 1.0%).

Exclusion criteria

Exclusion criteria: Patients who had a history of gut resection.

Design outcomes

Primary

Measure	Time frame
To evaluate the change of HbA1c of diabetes patients after transglucosidase treatment	—

Secondary

Measure	Time frame
To evaluate the change of fasting blood glucose, HOMA-IR, and intestinal microbiota of diabetes patients after transglucosidase treatment	—

Countries

Japan

Contacts

Public ContactMakoto Sasaki

Aichi Medical University Gastroenterology

msasaki@aichi-med-u.ac.jp+81-561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026